Breast Cancer | Specialty

Early Abemaciclib Data Not Sufficient to Halt Phase III Breast Cancer Trial

August 10th 2016

The phase III MONARCH 2 study assessing abemaciclib in HR-positive, HER2-negative advanced breast cancer will continue after the CDK4/6 inhibitor did not meet the efficacy criteria at an interim analysis required to stop the trial early.

Dr. Dixon on Prevalence and Risk Factors of Male Breast Cancer

August 10th 2016

J. Michael Dixon, MD, professor of Surgery, consultant surgeon, and clinical director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh in Scotland, discusses the prevalence of and risk factors for breast cancer in males.

Dr. Frankie Ann Holmes on Duel Anti-HER2-Directed Therapy in Breast Cancer

August 10th 2016

Dr. Arteaga on Ongoing Trials in Metastatic Breast Cancer

August 9th 2016

Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.

Dr. Lehman on 3D Mammography in Screening for Breast Cancer

August 8th 2016

Constance D. Lehman, MD, PhD, professor of radiology and chief of Breast Imaging in the Department of Radiology at Massachusetts General Hospital, discusses how 3D mammography has been an efficient and beneficial screening tool in the field of breast cancer.

Dr. Harold J. Burstein on CDK4/CDK6 Inhibitor Abemaciclib in Breast Cancer

August 7th 2016

​Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.

Dr. Kuerer on De-Escalating Surgery in the Treatment of Patients With Breast Cancer

August 5th 2016

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses de-escalating surgery in the treatment of patients with breast cancer.

FDA Grants Ribociclib Breakthrough Designation for Breast Cancer

August 3rd 2016

The FDA has granted a breakthrough therapy designation to the CDK4/6 inhibitor ribociclib in combination with letrozole for its potential as a frontline therapy for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Yardley on Unmet Need for Patients With HER2+ Breast Cancer

August 3rd 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the unmet need for patients with HER2-positive breast cancer.

Dr. Holmes Discusses Late Recurrence and the MA.17R Trial in Breast Cancer

July 30th 2016

Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment

July 29th 2016

Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.

Study Supports Use of Anthracyclines for Early, HER2-Negative Breast Cancer

July 29th 2016

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer, according to a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials.

Dr. Ma on the METRIC Trial in Triple-Negative Breast Cancer

July 28th 2016

Cynthia Ma, MD, PhD, associate professor of Medicine, Washington University School of Medicine, discusses the METRIC trial in triple-negative breast cancer.

Immunotherapy, Targeted Options Emerge in Triple-Negative Breast Cancer

July 28th 2016

Cynthia Ma, MD, provides insight on the potential of glembatumumab vedotin (CDX-011) and immunotherapies on the horizon in the field of triple-negative breast cancer.

Low Recurrence Score in Breast Cancer Shows No Survival Benefit With Chemo Plus Hormonal Therapy

July 28th 2016

Collective findings from clinical trials show that, for women with early-stage breast cancer who have a low 21-gene recurrence score, adding chemotherapy to standard hormonal therapy does not show a difference in survival.

Dual HER2-Targeted Approach Delivers Greatest Neoadjuvant Benefit in HER2+ Breast Cancer

July 28th 2016

In terms of neoadjuvant therapies for patients with HER2-positive breast cancer, dual anti–HER2-directed agents seem to have the most benefit.

Dr. Sparano on the Role of Endocrine Therapy in Breast Cancer

July 27th 2016

Joseph Sparano, MD, associate chairman, Clinical Research, Department of Oncology, Montefiore Medical Center, associate director, Clinical Research, Albert Einstein Cancer Center, discusses the ways in which the role of endocrine therapy has evolved over the years as a treatment for patients with breast cancer.

Less Treatment May Show Greater Benefit in Low-Risk Breast Cancer

July 27th 2016

Although there has been in increase in promising novel regimens available for patients with breast cancer in recent years, oncologists should carefully consider whether each agent would provide a significant enough benefit to offset its associated toxicities, cost, and the time and commitment by the patient it requires.

Expert Shares How Neoadjuvant Trials for TNBC Will Improve Treatment Decisions

July 25th 2016

Recent findings from clinical trials exploring neoadjuvant treatment in patients with triple-negative breast cancer may provide answers to several questions surrounding early-stage disease.

Neratinib Benefit in Breast Cancer Sustained in 5-Year ExteNET Analysis

July 22nd 2016

A 5-year assessment showed that neratinib reduced the risk of invasive disease recurrence or death by 26% compared with placebo as extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.